NR1H4 and metabolic dysfunction-associated steatohepatitis: Experimental evidence has shown that targeting bile acid pathways with FXR and TGR5 agonists, such as obeticholic acid, can reduce hepatic steatosis and inflammation, highlighting the potential of gut–liver axis therapies in managing NAFLD/NASH.